Alder Biopharmaceuticals
ALDR
ALDR was delisted on the 21st of October, 2019.
127 hedge funds and large institutions have $1.69B invested in Alder Biopharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 48 increasing their positions, 29 reducing their positions, and 11 closing their positions.
345% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 11
167% more capital invested
Capital invested by funds: $635M → $1.69B (+$1.06B)
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
66% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 29
43% more funds holding
Funds holding: 89 → 127 (+38)
59% less call options, than puts
Call options by funds: $2.66M | Put options by funds: $6.49M
Top Buyers
Top Sellers
ALDR Hedge Fund Activity: Q2 2015 in Review
127 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q2 2015, worth a combined $1.69B — up 167% from $635M a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new ALDR positions and 11 closed out — a net gain of 38 holders — while 48 added to existing stakes and 29 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $204M. The largest seller was Novo Holdings A/S, cutting an estimated $45.5M.
- 127 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q2 2015, up from 89 in Q1 2015.
- Funds reported $1.69B of Alder Biopharmaceuticals stock for Q2 2015, up 167% quarter-over-quarter.
- 49 funds opened new Alder Biopharmaceuticals positions in Q2 2015 and 11 closed out, a net change of +38 holders.
- The largest Alder Biopharmaceuticals buyer in Q2 2015 was Fidelity Investments, an estimated $204M added.
- The largest Alder Biopharmaceuticals seller in Q2 2015 was Novo Holdings A/S, an estimated $45.5M sold.
Based on aggregated 13F filings for Q2 2015.